BioAtla, Inc. (NASDAQ:BCAB – Get Free Report) saw a large decrease in short interest during the month of July. As of July 15th, there was short interest totalling 3,980,000 shares, a decrease of 24.2% from the June 30th total of 5,250,000 shares. Based on an average trading volume of 880,600 shares, the days-to-cover ratio is presently 4.5 days.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on BCAB shares. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of BioAtla in a research report on Wednesday, May 15th. JMP Securities lowered their target price on shares of BioAtla from $12.00 to $5.00 and set a “market outperform” rating for the company in a report on Thursday, May 23rd.
View Our Latest Stock Report on BioAtla
BioAtla Price Performance
BioAtla (NASDAQ:BCAB – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.09. Sell-side analysts predict that BioAtla will post -1.6 earnings per share for the current year.
Institutional Investors Weigh In On BioAtla
Several institutional investors have recently bought and sold shares of BCAB. Panagora Asset Management Inc. grew its stake in BioAtla by 110.0% during the fourth quarter. Panagora Asset Management Inc. now owns 111,366 shares of the company’s stock worth $274,000 after buying an additional 58,336 shares during the period. Pale Fire Capital SE grew its stake in BioAtla by 204.6% during the fourth quarter. Pale Fire Capital SE now owns 48,383 shares of the company’s stock worth $119,000 after buying an additional 32,500 shares during the period. Perceptive Advisors LLC purchased a new stake in BioAtla during the fourth quarter worth approximately $180,000. PVG Asset Management Corp purchased a new stake in BioAtla during the fourth quarter worth approximately $161,000. Finally, Chase Investment Counsel Corp acquired a new position in shares of BioAtla during the first quarter worth $263,000. 77.23% of the stock is currently owned by hedge funds and other institutional investors.
About BioAtla
BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
Further Reading
- Five stocks we like better than BioAtla
- Find and Profitably Trade Stocks at 52-Week Lows
- Why Call Options Volume for These 2 Stocks Spiked Together
- How Can Investors Benefit From After-Hours Trading
- MarketBeat Week in Review – 7/22 – 7/26
- The 3 Best Retail Stocks to Shop for in August
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.